Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcoma

• Published in: Human pathology Vol. 44; no. 9; pp. 1918 - 1926
• Main Authors: Charbonneau, Bridget, Vogel, Rachel Isaksson, Manivel, J. Carlos, Rizzardi, Anthony, Schmechel, Stephen C, Ognjanovic, Simona, Subramanian, Subbaya, Largaespada, David, Weigel, Brenda
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2013; Elsevier Limited
• Subjects: Adult; Disease Progression; Female; Humans; Local recurrence; Male; Metastasis; Minnesota - epidemiology; Pathology; Polyclonal antibodies; Polymerase chain reaction; Prognosis; Receptor, Fibroblast Growth Factor, Type 3 - metabolism; Receptor, Fibroblast Growth Factor, Type 4 - metabolism; Risk Factors; Sarcoma, Synovial - metabolism; Sarcoma, Synovial - mortality; Sarcoma, Synovial - pathology; Soft Tissue Neoplasms - metabolism; Soft Tissue Neoplasms - mortality; Soft Tissue Neoplasms - pathology; Soft tissue sarcoma; Studies; Surgery; Survival Rate; Tissue microarray; Tumors; Minnesota; Soft tissue sarcoma; Tissue microarray; Metastasis; Local recurrence
• ISSN: 0046-8177; 1532-8392
• DOI: 10.1016/j.humpath.2013.03.001

Summary Although rare, synovial sarcoma (SS) is one of the most common soft tissue sarcomas affecting young adults. To investigate potential tumor markers related to synovial sarcoma prognosis, we carried out a single-institution retrospective analysis of 103 patients diagnosed with SS between 1980 and 2009. Clinical outcome data were obtained from medical records, and archived tissue samples were used to evaluate the relationship between progression-free survival (PFS) and several prognostic factors, including tumor expression of FGFR3 and FGFR4. No associations were found between PFS and gender, body mass index, tumor site, SS18-SSX translocation, or FGFR4 expression. As seen in previous studies, age at diagnosis (<35, 63% versus ≥35 years, 31% 10-year PFS; P = .033), histologic subtype (biphasic, 75% versus monophasic 34% 10-year PFS; P = .034), and tumor size (≤5 cm, 70% versus >5 cm, 22% 10-year PFS; P < .0001) were associated with PFS in SS patients. In addition, in a subset of patients with available archived tumor samples taken prior to chemotherapy or radiation (n = 34), higher FGFR3 expression was associated with improved PFS ( P = .030). To the best of our knowledge, this is the largest study of SS to date to suggest a potential clinical role for FGFR3. While small numbers make this investigation somewhat exploratory, the findings merit future investigation on a larger scale.